These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 8817830)
81. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. Murphy SC; Deye GA; Sim BKL; Galbiati S; Kennedy JK; Cohen KW; Chakravarty S; Kc N; Abebe Y; James ER; Kublin JG; Hoffman SL; Richie TL; Jackson LA PLoS Pathog; 2021 May; 17(5):e1009594. PubMed ID: 34048504 [TBL] [Abstract][Full Text] [Related]
82. Strain-specific protective effect of the immunity induced by live malarial sporozoites under chloroquine cover. Wijayalath W; Cheesman S; Tanabe K; Handunnetti S; Carter R; Pathirana S PLoS One; 2012; 7(9):e45861. PubMed ID: 23029282 [TBL] [Abstract][Full Text] [Related]
83. Editorial: The First Monoclonal Antibody Vaccine to Prevent Malaria Heralds a New Era of Malaria Vaccines to the Plasmodium falciparum Circumsporozoite Protein (PfCSP). Parums DV Med Sci Monit; 2021 Sep; 27():e934676. PubMed ID: 34511592 [TBL] [Abstract][Full Text] [Related]
84. Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission. Tall A; Sokhna C; Perraut R; Fontenille D; Marrama L; Ly AB; Sarr FD; Toure A; Trape JF; Spiegel A; Rogier C; Druilhe P Malar J; 2009 Jul; 8():161. PubMed ID: 19604389 [TBL] [Abstract][Full Text] [Related]
85. Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites. Finney OC; Keitany GJ; Smithers H; Kaushansky A; Kappe S; Wang R Vaccine; 2014 Apr; 32(19):2135-8. PubMed ID: 24582635 [TBL] [Abstract][Full Text] [Related]
86. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Kublin JG; Lowitt MH; Hamilton RG; Oliveira GA; Nardin EH; Nussenzweig RS; Schmeckpeper BJ; Diggs CL; Bodison SA; Edelman R Vaccine; 2002 Mar; 20(13-14):1853-61. PubMed ID: 11906775 [TBL] [Abstract][Full Text] [Related]
90. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Edelman R; Wasserman SS; Kublin JG; Bodison SA; Nardin EH; Oliveira GA; Ansari S; Diggs CL; Kashala OL; Schmeckpeper BJ; Hamilton RG Vaccine; 2002 Dec; 21(3-4):269-80. PubMed ID: 12450702 [TBL] [Abstract][Full Text] [Related]
91. Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial. Nouatin O; Ibáñez J; Fendel R; Ngoa UA; Lorenz FR; Dejon-Agobé JC; Edoa JR; Flügge J; Brückner S; Esen M; Theisen M; Hoffman SL; Moutairou K; Luty AJF; Lell B; Kremsner PG; Adegnika AA; Mordmüller B Malar J; 2022 Jun; 21(1):191. PubMed ID: 35715803 [TBL] [Abstract][Full Text] [Related]
92. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. Lyke KE; Laurens M; Adams M; Billingsley PF; Richman A; Loyevsky M; Chakravarty S; Plowe CV; Sim BK; Edelman R; Hoffman SL PLoS One; 2010 Oct; 5(10):e13490. PubMed ID: 21042404 [TBL] [Abstract][Full Text] [Related]
93. Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination. Thompson HA; Hogan AB; Walker PGT; White MT; Cunnington AJ; Ockenhouse CF; Ghani AC Vaccine; 2020 Nov; 38(47):7498-7507. PubMed ID: 33041104 [TBL] [Abstract][Full Text] [Related]